Pharmacokinetics of Ghrelin
|Study Design:||Allocation: Randomized
Endpoint Classification: Pharmacokinetics/Dynamics Study
Intervention Model: Crossover Assignment
Primary Purpose: Treatment
|Official Title:||Pharmacokinetics of Ghrelin in Normal Subjects|
- Human ghrelin half life in healthy subjects
- Cardiovascular indices (stroke-velocity index, TEI-index)
|Study Start Date:||March 2005|
|Estimated Study Completion Date:||January 2006|
Ghrelin is a recently described acylated peptide hormone produced by the enteroendocrine cells of the mucosal epithelial layer in the ventricle. Ghrelin is the endogenous ligand for the growth hormone (GH) secretagogue receptor (GHS-R).
Ghrelin stimulates pituitary GH release by binding to the GHS-R at both hypothalamic and pituitary levels.
Several studies show that bolus injections of ghrelin have positive effects on cardiac function in healthy humans as well as in humans with cardiac disease. We investigate the changes in cardiac function during ghrelin infusion in healthy subjects.
The pharmacokinetics of ghrelin is described in few studies only, and we aim to elucidate this aspect further.
Comparisons: In a double blind, placebo controlled, cross over study we investigate the effect of 180 minutes ghrelin infusion on 1. cardiac function (tissue Doppler, stroke-velocity index), 2. vascular tone (a. brachialis dilatation), 3. ghrelin-half-life (acylated and des-acylated) and other pharmacokinetic parameters and 4. effect on appetite.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00116025
|Aarhus University Hospital|
|Aarhus, Denmark, 8000|
|Principal Investigator:||Jens Otto L Jorgensen, DrMedSc||Aarhus University Hospital|